BRAF and MEK Inhibitors: A Targeted Approach for Low-Grade Serous Ovarian Cancer

BRAF and MEK inhibitors represent a promising targeted therapy approach for certain types of ovarian cancer, particularly low-grade serous ovarian cancer (LGSOC). Unlike traditional chemotherapy that attacks all rapidly dividing cells, these drugs work by blocking specific proteins involved in cancer cell growth, offering new hope for patients whose tumors carry particular genetic mutations.

For decades, ovarian cancer treatment has relied heavily on surgery and platinum-based chemotherapy. But these standard treatments don’t work equally well for all ovarian cancer subtypes. LGSOC, which affects about 5 to 8% of ovarian cancer patients, tends to resist conventional chemotherapy. This is where targeted therapies like BRAF and MEK inhibitors come in.

Like PARP inhibitors that target DNA repair defects in high-grade serous ovarian cancer, BRAF and MEK inhibitors represent precision medicine, matching specific drugs to specific tumor characteristics. 

However, while PARP inhibitors work best in cancers with BRCA mutations, BRAF and MEK inhibitors target a different pathway altogether: the MAPK signaling pathway that’s often overactive in low-grade serous ovarian cancer. This distinction highlights why comprehensive genetic testing matters. Different mutations require different targeted treatments.

What Are MEK Inhibitors and How Do They Work?

MEK inhibitors are drugs that block proteins called MEK1 and MEK2. These proteins are part of a cellular signaling pathway known as the MAPK pathway (mitogen-activated protein kinase pathway), which controls how cells grow, divide, and survive.

Think of the MAPK pathway as a chain reaction inside your cells. When everything works normally, growth signals travel from the cell surface through a series of proteins: RAS, then RAF (including BRAF), then MEK, and finally ERK. Each protein activates the next one in line, eventually telling the cell nucleus whether to grow, divide, or die.

In many cancers, this pathway gets stuck in the “on” position due to mutations in genes like KRAS or BRAF. When that happens, cells receive constant signals to grow and divide, even when they shouldn’t. MEK inhibitors work by blocking the MEK proteins in this chain reaction, effectively cutting off the growth signals to cancer cells.

Blocking MEK1 and MEK2 may help keep cancer cells from growing and may kill them. This makes MEK inhibitors particularly useful when cancer cells have mutations that cause this pathway to be overactive.

Approved MEK Inhibitors: What’s Available?

Several MEK inhibitors have been approved by the FDA for treating melanoma, and researchers are now studying their potential in ovarian cancer. It’s important to note that none of these drugs are currently FDA-approved specifically for ovarian cancer — their use in LGSOC is considered off-label or investigational.

The main MEK inhibitors being studied in ovarian cancer include:

• Trametinib (Mekinist) was the first MEK inhibitor approved by the FDA for melanoma treatment. It’s typically used in combination with BRAF inhibitors for treating melanoma with BRAF mutations. Clinical trials have shown its potential in ovarian cancer, particularly LGSOC, though it remains investigational for this use.
• Cobimetinib (Cotellic) is approved for melanoma treatment in combination with BRAF inhibitors. It works similarly to trametinib by blocking the MEK proteins in the MAPK pathway and is being evaluated in ovarian cancer studies.
• Binimetinib (Mektovi) is approved for melanoma and has been studied extensively in ovarian cancer. The MILO/ENGOT-ov11 trial specifically evaluated binimetinib in patients with recurrent LGSOC.

These drugs are taken as oral tablets, making them more convenient than intravenous chemotherapy. Because they’re not yet FDA-approved for ovarian cancer, access typically requires participation in ovarian cancer clinical trials, off-label prescription by your oncologist, or compassionate use programs. Insurance coverage for off-label use varies and often requires prior authorization.

Understanding BRAF MEK Inhibitor Combinations

While MEK inhibitors can work alone, combining them with BRAF inhibitors has shown superior results in clinical trials. This combination approach targets the MAPK pathway at two different points, creating a more complete blockade of the cancer-promoting signals.

BRAF inhibitors include drugs like dabrafenib (Tafinlar), vemurafenib (Zelboraf), and encorafenib (Braftovi). When used alone, BRAF inhibitors can sometimes cause the MAPK pathway to activate through alternative routes: a phenomenon called paradoxical activation. Adding a MEK inhibitor prevents this workaround, making the treatment more effective and actually reducing certain side effects.

Research examining the safety profiles of these combination therapies found that while all-grade adverse events occurred in about 98% of patients receiving combination therapy, the specific toxicity profiles differed between drug pairs. This information helps doctors choose the most appropriate combination for each patient based on their other health conditions.

The combination of dabrafenib plus trametinib has shown particularly impressive results in melanoma, and researchers are now exploring its potential in ovarian cancer with similar mutations.

Why LGSOC Responds Differently to These Drugs

Low-grade serous ovarian cancer is fundamentally different from high-grade serous ovarian cancer (HGSOC) at the molecular level. While HGSOC typically has mutations in genes like TP53 and BRCA, LGSOC more commonly harbors mutations in the MAPK pathway: specifically, KRAS mutations and BRAF mutations.

Research has shown that approximately 50 to 60% of LGSOC patients harbor mutually exclusive mutations in KRAS (33 to 50% of cases), BRAF (5 to 20%, primarily V600E), or NRAS (5 to 10%). Beyond these canonical mutations, additional MAPK pathway alterations include NF1 loss, MAP2K1 mutations, and ERBB2 activation, collectively affecting up to 60-70% of LGSOC cases when considering the full spectrum of pathway dysregulation.

This genetic profile makes LGSOC uniquely suited to treatment with MAPK pathway inhibitors. The cancer’s growth depends heavily on the overactive MAPK pathway, so blocking this pathway can have dramatic effects on tumor growth.

LGSOC also tends to affect younger women. The median age at diagnosis is around 45 years, compared to 62.6 years for HGSOC. Many LGSOC patients are still of childbearing age, making the side effect profiles and fertility implications of treatment particularly important considerations.

Clinical Evidence: What the Research Shows

The landmark GOG 281/LOGS trial demonstrated that trametinib significantly improved outcomes for LGSOC patients, with median progression-free survival of 13 months compared to 7.2 months with standard chemotherapy. 

The overall response rate was 26%, and patients benefited regardless of their specific MAPK mutation status. 

For patients with BRAF V600E mutations, combining BRAF and MEK inhibitors has shown particularly impressive results, with some achieving complete responses lasting years. While clinical benefit rates reach 87% in LGSOC patients treated with MEK inhibitors, response rates and duration vary, underscoring why comprehensive genetic testing matters for treatment decisions.

MEK Inhibitors vs. Standard Treatment

For recurrent LGSOC, traditional options include chemotherapy or hormonal therapy with drugs like letrozole or tamoxifen.

Chemotherapy yields response rates of just 10 to 15% in previously treated LGSOC. Hormonal therapy works differently: rather than shrinking tumors, it aims for disease stabilization. 

MEK inhibitors have shown promising results in LGSOC, with the GOG 281 trial demonstrating objective response rates of 26% for trametinib compared to just 6% for standard-of-care treatments. Clinical benefit rates can reach up to 87%. Plus, they’re oral pills taken at home rather than requiring infusion center visits. 

While side effects like nausea (grade 3-4 occurring in 9% of patients) and hair changes are possible, these tend to be less severe and less common than with traditional chemotherapy.

Side Effects and Management

Like all cancer treatments, BRAF and MEK inhibitors come with side effects. Understanding these helps patients and their care teams manage them effectively. Common side effects of MEK inhibitors include:

• Skin rash and acneiform eruptions
• Diarrhea and nausea
• Fatigue
• Peripheral edema (swelling)
• Elevated liver enzymes
• Ocular toxicities (eye problems that may occur without symptoms, requiring regular monitoring)

Research on BRAF and MEK inhibitor toxicities found that grade 3 or higher adverse events varied by combination: 44% with dabrafenib plus trametinib, compared to 68 to 72% with other BRAF/MEK combinations. The most common severe side effects included pyrexia (fever), rash, and hypertension. This difference in toxicity profiles can guide treatment selection.

One unique side effect of dabrafenib is fever, which occurred in about 50% of patients in some studies. However, this can often be managed with dose interruptions and low-dose corticosteroids.

While MEK inhibitors do cause side effects, many patients find them more tolerable than chemotherapy. Studies comparing MEK inhibitors to chemotherapy in LGSOC found no clinically significant difference in quality of life scores, and importantly, MEK inhibitors avoid some of chemotherapy’s most difficult side effects like severe hair loss and the need for infusion center visits. That said, individual experiences vary, and working closely with your care team to manage side effects is essential.

Who Should Consider These Treatments?

Not every ovarian cancer patient will benefit from BRAF and MEK inhibitors. These treatments are most appropriate for:

• Patients with low-grade serous ovarian cancer, particularly those who have progressed after standard chemotherapy. LGSOC is notoriously resistant to conventional chemotherapy, making targeted therapies an important option.
• Patients with confirmed MAPK pathway mutations, especially BRAF V600E mutations. Comprehensive tumor genomic profiling through next-generation sequencing can identify these mutations. While MEK inhibitors showed some benefit regardless of mutation status in the trametinib trial, the strongest responses occur in patients with confirmed pathway alterations.
• Patients who have exhausted standard treatment options and are looking for alternatives. Since these drugs are not yet standard first-line treatment for ovarian cancer, they’re often considered after conventional approaches have failed.
• Younger patients concerned about fertility preservation might prefer these oral medications over repeated cycles of toxic chemotherapy, though this should be discussed thoroughly with an oncologist.

The Importance of Genetic Testing

Genetic testing of your tumor tissue is essential to determine if BRAF and MEK inhibitors might work for you. A test called next-generation sequencing looks for mutations in KRAS, BRAF, and NRAS: the genes that drive LGSOC growth.

Your doctor will send a tissue sample (from your original surgery or a biopsy) to a specialized lab, and results typically come back within 2 to 3 weeks. If you have a BRAF V600E mutation, you may be a candidate for combination BRAF and MEK inhibitor therapy. If you have KRAS or other MAPK pathway mutations, MEK inhibitor therapy alone might be an option.

Read more: “Genetic Testing for LGSOC: What Your Genes Can Tell You”

BRAF and MEK Inhibitors: Looking Ahead

BRAF and MEK inhibitors represent a fundamental shift toward personalized treatment based on your tumor’s specific mutations. LGSOC is biologically distinct from HGSOC, so it requires different treatments. While not a cure, these drugs can provide meaningful disease control for years with manageable side effects.

If you’ve been diagnosed with LGSOC:

• Get comprehensive tumor testing for KRAS, BRAF, and NRAS mutations
• Consult a gynecologic oncologist who specializes in these treatments
• Ask about clinical trials on ClinicalTrials.gov (search “MEK inhibitor LGSOC”)
• Join ovarian cancer support groups to connect with other LGSOC patients

While we still need larger clinical trials and longer follow-up data, the evidence accumulated so far on BRAF and MEK inhibitors is encouraging.

The future likely involves even more sophisticated combinations, better biomarker selection to identify which patients will benefit most, and strategies to overcome or prevent resistance. 

If you or a loved one is navigating an ovarian cancer diagnosis, remember: you’re not alone in this journey. Knowledge is power, and understanding your treatment options — including emerging targeted therapies — empowers you to make informed decisions about your care.